Dimensional Fund Advisors LP Purchases 123,240 Shares of Zymeworks Inc. (NYSE:ZYME)

Dimensional Fund Advisors LP lifted its position in Zymeworks Inc. (NYSE:ZYME) by 14.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 972,742 shares of the company’s stock after purchasing an additional 123,240 shares during the quarter. Dimensional Fund Advisors LP owned 1.41% of Zymeworks worth $14,240,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Jump Financial LLC acquired a new position in shares of Zymeworks in the 4th quarter valued at $712,000. Walleye Capital LLC acquired a new position in Zymeworks in the fourth quarter worth about $6,629,000. XTX Topco Ltd acquired a new position in Zymeworks in the fourth quarter worth about $493,000. Barclays PLC lifted its stake in Zymeworks by 43.1% during the fourth quarter. Barclays PLC now owns 220,890 shares of the company’s stock worth $3,234,000 after purchasing an additional 66,506 shares during the period. Finally, Sterling Capital Management LLC boosted its holdings in Zymeworks by 781.5% during the fourth quarter. Sterling Capital Management LLC now owns 1,719 shares of the company’s stock valued at $25,000 after purchasing an additional 1,524 shares in the last quarter. 92.89% of the stock is owned by institutional investors.

Zymeworks Trading Down 0.2 %

Shares of ZYME stock opened at $11.32 on Friday. Zymeworks Inc. has a 1 year low of $8.21 and a 1 year high of $17.70. The firm’s 50 day moving average is $11.88 and its 200-day moving average is $13.46. The firm has a market capitalization of $787.61 million, a price-to-earnings ratio of -7.55 and a beta of 1.24.

Zymeworks (NYSE:ZYME) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. Zymeworks had a negative return on equity of 23.00% and a negative net margin of 182.75%. Zymeworks’s quarterly revenue was up 170.3% compared to the same quarter last year. During the same period last year, the business posted ($0.42) EPS. On average, equities research analysts forecast that Zymeworks Inc. will post -1.39 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Zymeworks news, Director Ecor1 Capital, Llc bought 4,397 shares of the company’s stock in a transaction on Monday, March 31st. The stock was bought at an average price of $11.75 per share, for a total transaction of $51,664.75. Following the transaction, the director now owns 17,259,548 shares of the company’s stock, valued at approximately $202,799,689. The trade was a 0.03 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders bought a total of 1,350,347 shares of company stock worth $16,137,499 over the last three months. 1.92% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Lifesci Capital initiated coverage on Zymeworks in a research report on Tuesday, March 11th. They set an “outperform” rating and a $30.00 target price for the company. Citigroup lifted their price objective on Zymeworks from $18.00 to $19.00 and gave the company a “buy” rating in a report on Friday, March 7th. Finally, HC Wainwright upped their target price on shares of Zymeworks from $12.00 to $13.00 and gave the stock a “neutral” rating in a report on Monday, March 10th. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.